Transcutaneous Posterior Tibial Nerve Stimulation for Premature Ejaculation
Status:
Not yet recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Objective: Evaluate the effectiveness and safety of transcutaneous electrostimulation of the
posterior tibial nerve alone and combined with standard pharmacological treatment, in men
with primary premature ejaculation, compared to standard pharmacological treatment.
Patients and methods: Randomized controlled clinical trial. Patients diagnosed with premature
ejaculation attending Boston Medical Group clinics in Colombia and Spain will be included.
Participants will be assigned by randomization to one of three treatment groups:
- Group 1: Tens + placebo drug therapy
- Group 2: Standard treatment (paroxetine 20 mg) + placebo therapy
- Group 3: Tens therapy + standard treatment (paroxetine mg)
The change in intravaginal latency time measured with the couple's sustained stopwatch, the
change in the PEDT scale, the perception of the change in their initial condition after
treatment (Global Clinical impression of change scale), and the change in different domains
of the EP (PEP Scale - Profile Ejaculation Premature) at the end of treatment (week 12) and
at three months of follow-up (week 24).